Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug

Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, is making a gutsy move into the cutting edge of cancer treatment, spending $11.9 billion in cash to buy Kite Pharma, developer of a treatment that attacks tumors by genetically modifying patients ’ own white blood cells.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:GILD NASDAQ:KITE NASDAQ:JUNO Source Type: news